Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer, Gerd; Nelson, Mark; Lazzarin, Adriano; Konourina, Irina; I M Hoepelman, Andy; Lampiris, Harry; Hirschel, Bernard; Tebas, Pablo; Raffi, François; Trottier, Benoit; Bellos, Nicholaos; Saag, Michael; A Cooper, David; Westby, Mike; Tawadrous, Margaret; F Sullivan, John; Ridgway, Caroline; W Dunne, Michael; Felstead, Steve; Mayer, Howard; van der Ryst, Elna; 1 and MOTIVATE 2 Study Teams, MOTIVATE

doi:10.1056/NEJMoa0803154

Public

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Shared by NobleBlocks on Oct 2, 2008 • 12:00 AM UTC

Authors:

Gerd Fätkenheuer

Mark Nelson

Adriano Lazzarin

Abstract

BACKGROUND: We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize the efficacy and safety of maraviroc in key subgroups of patients. METHODS: We an...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!